key: cord-1036496-bggfy0j2
authors: Min, Yuan-Qin; Huang, Mengzhuo; Sun, Xiulian; Deng, Fei; Wang, Hualin; Ning, Yun-Jia
title: Immune evasion of SARS-CoV-2 from interferon antiviral system
date: 2021-07-26
journal: Comput Struct Biotechnol J
DOI: 10.1016/j.csbj.2021.07.023
sha: a8ccd37f3981be9afe8022fa8dd49081b958b6a6
doc_id: 1036496
cord_uid: bggfy0j2

The on-going pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to unprecedented medical and socioeconomic crises. Although the viral pathogenesis remains elusive, deficiency of effective antiviral interferon (IFN) responses upon SARS-CoV-2 infection has been recognized as a hallmark of COVID-19 contributing to the disease pathology and progress. Recently, multiple proteins encoded by SARS-CoV-2 have been shown to act as potential IFN antagonists with diverse possible mechanisms. Here, we summarize and discuss the strategies of SARS-CoV-2 for evasion of innate immunity (particularly the antiviral IFN responses), understanding of which will facilitate not only the elucidation of SARS-CoV-2 infection and pathogenesis but also the development of antiviral intervention therapies.

The emergence of a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quickly caused the global pandemic of coronavirus disease 2019 (COVID- 19) .

As of April 29, 2021, more than 149 million confirmed cases with over 3 SARS-CoV-2 infection starts with the attachment of the S protein to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and other entry cofactors, followed by virus-cell membrane fusion, genome release, RNA transcription/replication, protein production, and virion assembly and budding 2 . Upon viral infection, host cells generally respond by recognizing particular molecular structures (called pathogen-associated molecular patterns, PAMPs, e.g. foreign viral RNAs) introduced or produced in viral life cycle to trigger innate immune responses 3 . As the first line of host defense, innate immunity and especially the antiviral interferon (IFN) system restrict viral replication and spread, promote tissue repair, and aid in development of the subsequent adaptive immunity, eventually facilitating viral clearance [4] [5] [6] . However, extraordinarily, IFN responses seem to be weak during SARS-CoV-2 infection, indicating efficient counteraction of the antiviral system by SARS-CoV-2 [7] [8] [9] . This deficiency of IFN responses likely leads to productive viral replication and contributes to COVID-19 pathology and severity 8, [10] [11] [12] . Therefore, elucidation of the interactions of SARS-CoV-2 with IFN system will not only provide pivotal insights into SARS-CoV-2 infection and pathogenesis but also benefit design of prophylaxis and treatment against COVID- 19 . In this review, we summarize the recent progress on the evasion strategies of SARS-CoV-2 from host innate immunity and in particular the antiviral 4 / 26 IFN system and discuss significant future directions for further study.

Antiviral IFN system based on type I IFNs (especially IFN- and IFN-β) and type III IFNs (IFN-) plays essential roles in host defense against viral infections by acting as a primary component of innate immunity and promoting the induction of adaptive immunity [4] [5] [6] . Responses of the antiviral IFN system comprise two phases, IFN induction and IFN action (also called IFN signaling) (Figure 1 ).

PAMPs (mainly specific viral nucleic acids or some other particular products of viral infection) via cellular pattern recognition receptors (PRRs). PRRs sensing RNA virus infections mainly include cytosolic RIG-I-like receptors (RLRs) and transmembrane toll-like receptors (TLRs, residing on cell surface or in endosomes). For immune recognition of coronavirus infections, RLRs, melanoma differentiation-associated protein 5 (MDA5) and retinoic acid-inducible gene I (RIG-I), and TLRs, TLR3 and TLR7, are usually considered to play notable roles in sensing various viral RNAs and leading to type I and III IFN production [13] [14] [15] [16] . TLR3 in endosomes can detect viral double-stranded RNA (dsRNA) and then activate the downstream adaptor protein Toll/IL-1 receptor (TIR) domain-containing adaptor (TRIF), while viral single-stranded RNA (ssRNA) can be recognized by TLR7, thus triggering the downstream adaptor protein myeloid differentiation primary response gene 88 (MyD88) 15, 17 . In the cytoplasm, viral RNA PAMPs activate RIG-I and MDA5 which subsequently induce the activation of their common adaptor, mitochondrial antiviral signaling protein (MAVS) 18, 19 . These PRR-adaptor signaling cascades continue with the downstream kinases, TANK binding kinase 1 (TBK1) and inhibitor of κB kinase ε (IKKε), and IKKα, IKKβ and IKKγ. TBK1 and IKKε phosphorylate and hence activate transcription factors IFN regulatory factor 3 (IRF3) and IRF7, while IKKα, IKKβ and IKKγ direct the activation of transcription factor nuclear factor-κB (NF-κB). Then activated transcription factors translocate to the nucleus, inducing expression of type I and III IFNs, some IFN-stimulated gene (ISGs), and proinflammatory cytokines 18 . In addition, the cGAS (cyclic GMP-AMP synthase)-STING (stimulator of interferon genes) pathway that is commonly associated with sensing of cytosolic DNA PAMPs may be also activated by SARS-CoV-2 infections 20, 21 , perhaps 5 / 26 due to the DNA release from damaged mitochondria or nuclei, although to what extent it would contribute to the anti-SARS-CoV-2 immune responses is uncertain. In this pathway, cGAS senses and is activated by DNA PAMPs 22, 23 . Subsequently, activated cGAS catalyzes the synthesis of 2'3'-cyclic GMP-AMP (2'3'-cGAMP) that binds to STING as the secondary messenger to activate TBK1 and other IKKs, then directing similar downstream signaling cascades to induce expression of the antiviral IFNs and other immune regulatory genes 22-24 .

In the following IFN action phase, type I and III IFNs establish the cellular state of viral resistance in infected cells and adjacent cells through autocrine and paracrine pathways, 

Most, if not all, pathogenic viruses evolve their evasion strategies against innate immune [29] [30] [31] [32] . Based on the related findings of SARS-CoV-2 and combined with the knowledge from other coronaviruses (especially SARS-CoV), the innate immune evasion strategies of SARS-CoV-2 could be categorized as follows: (i) inhibiting IFN induction, including concealing or reducing PAMPs to evade host PRR sensing or disrupting the following signaling cascades of IFN induction; (ii) suppressing IFN action; (iii) globally interfering with production of host proteins including IFNs (Figure 1 ).

induction. SARS-CoV-2 may have evolved strategies to counteract the host defense at this very early stage by concealing or decreasing potential PAMPs ( Figure 1 ). Like most positive-strand RNA viruses, SARS-CoV-2 induces cellular endomembrane remodeling to form double membrane vesicles (DMVs), which compartmentalize and facilitate viral RNA replication and thus likely prevents viral RNA PAMPs from exposure to cellular PRRs [33] [34] [35] . The N protein plays essential roles in SARS-CoV-2 genome packaging by encapsidation and intriguingly, seems to undergo liquid-liquid phase separation with RNA which might also contribute to the concealing of viral RNA PAMPs and merits further investigation [36] [37] [38] . Furthermore, SARS-CoV-2 can methylate the 5'-end of viral mRNA by nsp16/nsp10 heterodimer to mimic cellular mRNA, hijacking the host translation machinery and evading PRR recognition 39 . Like SARS-CoV, SARS-CoV-2 has a self-coded capping machinery composed of nsp10, nsp12, nsp13, nsp14, and nsp16 [39] [40] [41] [42] [43] . nsp13, the viral helicase, also has an RNA triphosphatase activity 44, 45 which initiates the formation of an RNA cap and moreover, likely reduces 5'-triphosphorylated viral RNA, an otherwise potential PAMP sensed by host PRRs (especially RIG-I). nsp12, RdRp-associated nucleotidyltransferase (NiRAN), possesses guanylyltransferase activity, catalyzing the formation of cap core structure (GpppA) 43 . nsp14, an mRNA cap guanine-N7-methyltransferase, produces a Cap-0 ( me7 G o pppA 1 ) 40, 42 . nsp16, a cap ribose 2′-O-methyltransferase, forms an obligatory complex with nsp10 to efficiently convert mRNA species from the Cap-0 to the Cap-1 ( me7 G o pppA 1m ) 39 .

Modified viral RNA can evade recognition by host PRRs, including RLRs and TLRs, and may also avoid the antiviral effects of some other ISGs such as interferon-induced proteins with tetratricopeptide repeats (IFIT) 46 . In addition, coronavirus nsp15 is an uridylate-specific endoribonuclease (designated EndoU) that seems to cleave 5′-polyuridines from negative-sense viral RNA (the product of polyA-templated RNA synthesis; potential PAMP triggering MDA5), significantly circumventing activation of MDA5 [47] [48] [49] . Considering the high conservativeness of the EndoU activity among coronaviruses, this evasion strategy previously demonstrated in the studies of other coronaviruses is very likely employed by SARS-CoV-2 as well, although direct testing of the SARS-CoV-2 nsp15 activity is required for validation. These possible strategies are summarized in Table 1 .

Aside from the passive stashing of PAMPs, SARS-CoV-2 also has been equipped with multiple active immune antagonists that can directly target to the PRR-triggered signaling cascades to dampen IFN induction (Table 1 and Figure 1 ). The N protein of SARS-CoV-2 may bind to the DExD/H domain of RIG-I, which has ATPase activity and is important for the binding of PAMP RNAs, thus impeding RIG-I signaling 50, 51 The stress granule protein G3BP1 that positively regulates innate immune responses including RIG-I signaling was observed to be recruited in the phase separated condensates of SARS-CoV-2 N 37 ; it will be interesting to investigate whether RIG-I could be also recruited into SARS-CoV-2 N condensates and whether the recruitment of the host proteins in the condensates could contribute to viral inhibition of IFN induction. Another SARS-CoV-2 structural protein, M, also was shown to inhibit the antiviral IFN polyproteins, resulting in the release of nsp1, nsp2, and nsp3, while 3-chymotrypsin-like "main" protease (3CLpro or Mpro, harbored in nsp5) is responsible for the cleavage and hence mature of the other nsp proteins [54] [55] [56] . SARS-CoV-2 3CLpro was demonstrated to interact with RIG-I as well and thus obstruct K63-linked ubiquitination and activation of RIG-I by E3 ligase tripartite motif 25 (TRIM25) 57 . As for PLpro, besides the protease activity, it may also act as a deubiquitinase (DUB) and a deISGylase that directly remove ubiquitin or ubiquitin-like ISG15 modifications required for multiple signaling protein activation events, crippling innate immune signaling transduction [58] [59] [60] . SARS-CoV-2 PLpro shares ~83% sequence identity with its counterpart in SARS-CoV but show a different preference for substrates ubiquitin and ISG15 [61] [62] [63] . SARS-CoV PLpro disrupts ubiquitination but with a lesser effect on ISGylation, while SARS-CoV-2 PLpro exhibits notable preference for cleaving ISG15 from host protein substrates and in particular MDA5 and IRF3, therefore attenuating IFN induction 61, 64 . Additionally, SARS-CoV-2 PLpro may also directly cleave IRF3 to suppress IFN production 65 . Importantly, PLpro inhibitors can reverse PLpro-mediated suppression of type I IFN induction and attenuate SARS-CoV-2 replication 61 , highlighting the dual intervention potential of these inhibitors against SAR-CoV-2 and COVID-19 that may not only inhibit viral nsp replicase mature but also rescue host antiviral immunity.

SARS-CoV-2 ORF9b was shown to be localized to mitochondria and interact with translocase of outer mitochondrial membrane 70 (Tom70), a critical protein linking MAVS to TBK1 and IRF3, perhaps thus inhibiting type I IFN induction 66, 67 . Then, Wu et al. reported that ORF9b of SARS-CoV-2 appears to also target IKKγ, an essential regulator of NF-κB, and specifically interrupts IKKγ K63-linked polyubiquitination through its N-terminus, thereby inhibiting the IKKα/β/γ-NF-κB signaling and subsequent IFN promoter activation 68 . As stated above, SARS-CoV-2 nsp13 plays essential roles in viral replication as the helicase and 5'-triphosphatase;

notably, this viral protein also exhibits significant inhibitory capacity against IFN induction (as well as IFN action that is discussed in the following section). Mechanistically, SARS-CoV-2 nsp13 may bind TBK1 and impedes the association of TBK1 with other signaling proteins including MAVS and TNF receptor-associated factors (TRAFs, which facilitate recruitment of TBK1 to MAVS), suppressing TBK1 and IRF3 activation and IFN expression [69] [70] [71] . Interestingly, SARS-CoV-2 nsp6 appears to interact with TBK1 to inhibit IRF3 activation as well; however, unlike nsp13, nsp6 expression does not affect TBK1 phosphorylation/activation 71 Other viral proteins of SARS-CoV-2, including nsp12, nsp14, nsp15, ORF3b and ORF8, may also repress IFN induction 7, 70, [74] [75] [76] [77] [78] [79] . However, the underlying mechanisms are more elusive. Like ORF6, nsp12 inhibits IRF3 nuclear translocation, but not phosphorylation, induced by Sendai virus (a model RNA virus triggering innate immune responses) 7, 74 , suggesting that nsp12 may function at the level or downstream of IRF3. nsp14, nsp15, ORF3b and ORF8 were shown to impair nuclear translocation of IRF3 as well, but whether the activation of the transcription factor could be affected is unknown 70, 75, 79 . Moreover, the inhibitory capacity of ORF8 to interferon production is controversial 70, 75 . Suppression of IRF3 nuclear translocation is an experimental phenomenon which could be resulted by various interferences with the signaling events at the level of IRF3, or upstream or downstream. Thus, the exact cellular interaction targets of these SARS-CoV-2 proteins for IFN induction antagonism remain to be further determined. Despite the largely unclear mechanism, antagonistic activity of SARS-CoV-2 ORF3b to IFN induction likely depends on its C-terminal length 78, 79 . SARS-CoV-2 ORF3b is much shorter (22 amino acids) but appears to have greater capacity to antagonize Sendai virus infection-caused IFN promoter activation, in comparison with its SARS-CoV ortholog (153 amino acids). Moreover, interestingly, a natural SARS-CoV-2 ORF3b variant with extended C-terminus because of the loss of the first premature stop codon exhibited increased IFN-induction suppressive activity and was isolated from two severe COVID-19 cases 79 .

In addition to inhibiting the classical RNA virus-triggered immune pathways, it has been recently reported that SARS-CoV-2 may also be able to antagonize the cGAS-STING signaling cascades 20 . ORF3a was shown to selectively inhibit cGAS-STING pathway but not RLR response.

Mechanistically, ORF3a may interact with STING and block the nuclear accumulation of NF-κB, thus likely impeding IFN promoter activation in cGAS-STING signaling transduction. In comparison, 3CLpro seems to disturb both of the RLR (as described above) and cGAS-STING pathways. For the inhibition of cGAS-STING signaling, this viral protein was demonstrated to bind STING as well and abate its K63-ubiquitin modification, thus preventing STING functional complex assembly and downstream signaling 20 .

The IFN action phase also can be circumvented by SARS-CoV-2. In SARS-CoV-2 infected cells, IFN-stimulated nuclear translocation of STAT1 and STAT2 can be generally diminished 73 .

Several SARS-CoV-2 proteins may be involved here ( Figure 1 and Table 1 ). ORF6 ectopic expression was shown to abolish cellular STAT1 nuclear translocation but not phosphorylation driven by type I IFN treatment 7, 71, 73 . While the potential association of ORF6 with KPNAs as aforementioned appeared to be dispensable in the inhibition of IFN action, an interaction between ORF6 and nucleoporin 98 (Nup98) instead was shown to be important for the blockade of STAT1 nuclear import 67, 73 . Despite many controversial results existing in different reports, other proteins encoded by SARS-CoV-2 including ORF3a, ORF7a, ORF7b, nsp6, nsp13, M, and N may also dampen type I IFN action 7, 71, 80 . Therein, nsp6, nsp13, ORF7b, and N decrease both STAT1 and STAT2 phosphorylation 71, 80 ; ORF3a and M may mainly reduce STAT1 phosphorylation, while ORF7a may mainly inhibit STAT2 activation 71 . In the study by Xia et al., it was further demonstrated that SARS-CoV-2 nsp6 has a stronger activity of inhibiting IFN action compared with MERS-CoV nsp6, whereas SARS-CoV nsp6 exhibits no such activity at all 71 . More interestingly, replacement of SARS-CoV-2 nsp6 by its orthologs from SARS-CoV or MERS-CoV in the context of a SARS-CoV-2 replicon system decreased the ability of resistance to type I IFN treatment 71 . The observation further supports the significance of IFN action antagonism for viral fitness to host cells in a context more like that of viral authentic infection. However, similarly, as impairments of the signaling components and events at the level or upstream of STATs all might result in the diminishment of STAT activation, the direct cellular targets and mechanisms employed by these IFN action antagonists (including nsp6) need to be further uncovered.

As obligate intracellular parasites, viruses hijack host cell components to achieve their life cycles. In the course of infection, high-pathogenic coronaviruses likely have developed some strategies to globally interfere with production of host proteins including IFNs [81] [82] [83] . As for SARS-CoV-2, its nsp1, nsp8, nsp9, and nsp16 are likely involved in the disturbance of host protein synthesis or trafficking at various levels [84] [85] [86] [87] (Figure 1 and Table 2 ). SARS-CoV nsp1 is notable as a host shutoff factor inhibiting cellular mRNA translation and this activity is likely also conservative in other pathogenic β-and -coronaviruses, although the detailed mechanisms may differ 81, 88 . Recent studies have suggested that the nsp1 of SARS-CoV-2 is not exceptional. Additionally, SARS-CoV-2 nsp1 also interacts with the host mRNA export receptor heterodimer NXF1-NXT1 and prevents proper binding of NXF1 to mRNA export adaptors and NXF1 docking at the nuclear pore complex, rendering a significant number of cellular mRNAs retained in the nucleus and thus likely also contributing to the inhibition of host antiviral gene expression 84 .

Further, SARS-CoV-2 nsp16 was shown to bind pre-mRNA recognition domains of U1/U2 snRNAs and disrupt global mRNA splicing and mature, while the nsp8 and nsp9 proteins bind to the 7SL RNA in the signal recognition particle (SRP) and interfere with protein integration into cell membrane and trafficking 87 

The world is currently suffering from the pandemic of COVID-19 caused by SARS-CoV-2.

As a pivotal aspect of virus-host interactions and viral pathogenesis, the interplays of SARS-CoV-2 with host innate immune system have attracted many research interests that yield significant progress. However, we are still far from clearly understanding the complex immune vaccines. In addition to the mechanisms at the levels of viral RNAs and proteins, post-translation modification could be also involved in the viral immune antagonism. Particularly, the heavy glycosylation of SARS-CoV-2 S protein has been suggested to likely contribute to not only viral entry but also the escape from immune responses (including both antibody production and epitope recognition) [96] [97] [98] [99] [100] [101] , although it is unclear whether the glycosylated viral protein is implicated in SARS-CoV-2 counteraction of IFN-based innate immunity which we here focus on. Additionally, palmitoylation of SARS-CoV-2 S protein seems to be involved in the viral protein-mediated, cholesterol-dependent syncytia formation which may facilitate viral cell-to-cell spread and hence escape from the extracellular neutralizing antibodies and immune recognition receptors 38, 102, 103 .

Likewise, protein modification including glycosylation could differ among viral strains, cell types and individuals 97 . Therefore, it will be also interesting to address the effects of other viral and host factors, such as viral protein modification, cell types, and individual background, on the viral evasion from innate immunity and hence on the disease heterogeneity.

SARS-CoV-2 shares ~79.5% genomic sequence identity to its sister coronavirus SARS-CoV, while they exhibit notable differences in transmissibility and pathogenicity 104 With an extraordinarily large RNA genome, SARS-CoV-2 seems to be equipped with many IFN antagonists to interfere with multiple layers of the host antiviral IFN responses, which is likely a significant determinant for its well adaptation in human population as seen in the pandemic. Over the past year, a series of potential IFN antagonists with various possible mechanisms have been proposed as discussed here. However, greater efforts are undoubtedly needed to present a clearer and more comprehensive picture of the IFN antagonism of SARS-CoV-2. These efforts will help to not only understand the viral infection and pathogenesis but also develop novel antivirals and vaccines to combat the ongoing pandemic and to prepare better for dealing with the future outbreaks of emerging or re-emerging coronaviruses. :   Table 1 . Antagonism of IFN induction and action by SARS-CoV-2. 

A new coronavirus associated with human respiratory disease in China

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

SARS-CoV-2 infection and the antiviral innate immune response

Interferons and viruses: an evolutionary arms race of molecular interactions

Contribution of type III interferons to antiviral immunity: location, location, location

Induction and function of type I and III interferon in response to viral infection

Activation and evasion of type I interferon responses by SARS-CoV-2

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Dysregulation of type I interferon responses in COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Interferon deficiency can lead to severe COVID

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

The RNA sensor MDA5 detects SARS-CoV-2 infection

Interplay between SARS-CoV-2 and the type I interferon response

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Protective Role of Toll-like Receptor 3-Induced Type I Interferon in Murine Coronavirus Infection of Macrophages

Recognition of pathogen-associated molecular patterns by TLR family

Immunology of COVID-19: Current State of the Science

Discriminating self from non-self in nucleic acid sensing

Unique and complementary suppression of cGAS-STING and RNA sensing-triggered innate immune responses by SARS-CoV-2 proteins

SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-κB

Activates the Type I Interferon Pathway

Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects

Jak-Stat Pathways and Transcriptional Activation in Response to Ifns and Other Extracellular Signaling Proteins

From interferons to cytokines

All About the RNA: Interferon-Stimulated Genes That Interfere With Viral RNA Processes

Interferon-Stimulated Genes: A Complex Web of Host Defenses

Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways

Interferon-lambda orchestrates innate and adaptive mucosal immune responses

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures

Links between innate and adaptive immunity via type I interferon

A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis

A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping

Interaction of the innate immune system with positive-strand RNA virus replication organelles

The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA

The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein

SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation

Structural basis of RNA cap modification by SARS-CoV-2. Nat restriction by IFIT family members

Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors

Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication

Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages

SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-Like Receptor Pathways to Inhibit the Induction of Interferon Response

SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-beta Production

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling

SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response

Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity

Mechanisms and enzymes involved in SARS coronavirus genome expression

Processing of the human coronavirus 229E replicase polyproteins by the virus-encoded 3C-like proteinase: identification of proteolytic products and cleavage sites common to pp1a and pp1ab

Main protease of SARS-CoV-2 serves as a bifunctional molecule in restricting type I interferon antiviral signaling

Crystal Structure of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Papain-like Protease Bound to Ubiquitin Facilitates Targeted Disruption of Deubiquitinating Activity to Demonstrate Its Role in Innate Immune Suppression

Severe Acute Respiratory Syndrome Coronavirus Papain-Like Protease Ubiquitin-Like Domain and Catalytic Domain Regulate Antagonism of IRF3 and NF-kappa B Signaling

Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease

ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity

SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species

SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO

SARS-CoV-2 non-structural protein 13 (nsp13) hijacks host deubiquitinase USP13 and counteracts host antiviral immune response

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists

Evasion of Type I Interferon by SARS-CoV-2

Sarbecovirus ORF6 proteins hamper induction of interferon signaling

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation

The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

Structure of SARS-CoV-2 ORF8, a rapidly evolving immune evasion protein

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Loss of orf3b in the circulating SARS-CoV-2 strains

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2

Coronavirus nonstructural protein 1: Common and distinct functions in the regulation of host and viral gene expression

nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus

Sparing mRNAs of Cytoplasmic Origin

Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation

Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2

SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation

SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses

SARS-CoV-2 nsp1: Bioinformatics, Potential Structural and Functional Features, and Implications for Drug/Vaccine Designs

Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation

Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA

The viral protein NSP1 acts as a ribosome gatekeeper for shutting down host translation and fostering SARS-CoV-2 translation

Modeling the SARS-CoV-2 nsp1-5'-UTR complex via extended ensemble simulations

SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism

Genes with 5' terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 NSP1 protein

The coding capacity of SARS-CoV-2

Glycans of SARS-CoV-2 Spike Protein in Virus Infection and Antibody Production

Glycosylation is a key in SARS-CoV-2 infection

The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses

Inhibition of SARS-CoV-2 viral entry upon blocking N-and O-glycan elaboration

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The research in our laboratory was funded by the National Natural Science Foundation of China 

The authors declare no conflict of interest.